China Biologic Products (CBPO) Tops Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
China Biologic Reports Financial Results for the First Quarter of 2019
May 10, 2019 4:30 PM EDT--1Q19 Total Sales Up 15.4% YoY in USD terms, or 22.3% YoY in RMB terms;Net Income Up 19.3% YoY to $37.7 Million;Non-GAAP Adjusted Net Income Up 14.3% YoY in RMB terms --
BEIJING, May 10, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the first quarter of 2019.
First Quarter 2019 Financial Highlights
Total sales in the first quarter of 2019 increased by 22.3% in RMB terms and... More